SGO 2023 - Society of Gynecologic Oncology Annual Meeting on Women’s Cancer 2023
Mar 25 - Mar 28, 2023 | TampaFLUS
LARVOL is not affiliated with Society of Gynecologic Oncology Annual Meeting on Women’s Cancer 2023 and all trademarks, logos, and brand names are property of their respective owners
Showing 39 titles linked to Trials
Overall survival in NRG258, a randomized phase III trial of chemo-radiation vs. chemotherapy alone for locally advanced endometrial carcinoma
NRG GY018/Keynote-868: A Phase III Randomized, Placebo-Controlled Study of Pembrolizumab in Addition to Paclitaxel and Carboplatin for Measurable Stage III or IVA, Stage IVB or Recurrent Endometrial Cancer
NOW: NEOADJUVANT OLAPARIB WINDOW TRIAL IN PATIENTS WITH NEWLY DIAGNOSED BRCA MUTANT OVARIAN CANCER
Dostarlimab in combination with chemotherapy for the treatment of primary advanced or recurrent endometrial cancer: a placebo-controlled randomized phase 3 trial (ENGOT-EN6-NSGO/GOG-3031/RUBY)
GOG 3026 A Phase II Trial of Letrozole + Ribociclib in Women with Recurrent Low-Grade Serous Carcinoma of the Ovary, Fallopian Tube or Peritoneum: A GOG Foundation Study
Mirvetuximab soravtansine (MIRV) in patients with platinum-resistant ovarian cancer with high folate receptor alpha (FRα) expression: Evaluation of sequence of therapy on anti-tumor activity in the SORAYA study
A Phase II Trial Evaluating Cisplatin and Gemcitabine Concurrent with Intensity-Modulated Radiation Therapy (IMRT) for the Treatment of Locally Advanced Squamous Cell Carcinoma of the Vulva: NRG Oncology Trial #279
Botensilimab, a novel innate/adaptive immune activator, plus balstilimab (anti-PD-1) in patients with recurrent platinum refractory/resistant ovarian cancer
SOLAR: Phase Ib Dose Expansion of Selumetinib (MEK Inhibitor) and OLAparib (PARP Inhibitor) Combination in Solid Tumors with RAS Pathway Alterations and in PARP Inhibitor-Resistant Ovarian Cancer
Feasibility of circulating tumor DNA as a marker for treatment response and prognosis in in BRCA non-mutated patients with platinum-sensitive recurrent ovarian cancer (OPEB-01)
Seminal Presentation: Overall survival (OS) at 7-year (y) follow-up (f/u) in patients (pts) with newly diagnosed advanced ovarian cancer (OC) and a BRCA mutation (BRCAm) who received maintenance olaparib in the SOLO1/GOG-3004 trial
Final primary analysis in the original cohort of KGOG3046/TRU-D: a phase II study of durvalumab and tremelimumab with front-line neoadjuvant chemotherapy in patients with advanced-stage ovarian cancer
A randomized Phase II study of chemoradiation and pembrolizumab for locally advanced cervical cancer
Toripalimab combined with bevacizumab and chemotherapy for refractory, recurrent or metastatic cervical cancer: preliminary results of a single-arm, open-label, phase Ⅱ trial
Final overall survival and long-term safety in the ENGOT-OV16/NOVA phase III trial of niraparib in patients with recurrent ovarian cancer